KKUR Chromocure Inc (CE)

ChromoCure Inc. (PINKSHEETS: KKUR) announced today it has signed a Letter of Intent with Genome Research Group (GRG). Under the terms of the Agreement, ChromoCure will acquire and merge with GRG and combine the Company's operations and assets with all GRG Intellectual Property (IP) assets and operations.

The merger transaction is valued in excess of $25,000,000 and results in significant increases to shareholder equity and reductions in long-term liabilities. The Company had recently announced a Technology Exchange and Collaboration Agreement with GRG, and through the initial integration phase, determined that joining forces and merging technology and operations would be of mutual benefit in advancement of their shared objective as a focused Cancer Therapy and Cure Research & Development organization.

GRG's advanced Therapeutic Modeling Protocols, together with ChromoCure's landmark Chromosomal Scanning Technology, further strengthens the Company's leadership in Cancer Detection.

For More Information on ChromoCure please visit: www.chromocure.com.

For More Information on Genome Research Group please visit: www.genomeresearchgroup.com.

Other active stocks are Akorn Inc. (NASDAQ: AKRX), Forest Laboratories Ltd., (NYSE: FRX) and Pfizer Inc. (NYSE: PFE).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact: Eric Jensen Company: IONEWSWIRE.COM Phone: 1-516-942-4910